Logo

Montreal Heart Institute to Use $5.1M Grant on PGx Studies for ACS Drug

Oct 08, 2007
NEW YORK (GenomeWeb News) — The Montreal Heart Institute has been awarded a CAN$5 million ($5.1 million) grant to fund a research project based on its academic and private partnerships in pharmacogenomics, MHI said late last week.
 
The funding was awarded as part of a Genome Quebec competition aimed at fostering public and private participation in developing personalized medical technologies.
 
As GenomeWeb Daily News reported last week, MHI will partner with VIA Pharmaceuticals to perform genomics and proteomics studies and to develop a genotyping panel that the company could use in Phase II clinical trials for an acute coronary syndrome drug.

Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.